Adalimumab (Humira)
Title: Adalimumab (Humira)Category: MedicationsCreated: 10/16/2018 12:00:00 AMLast Editorial Review: 10/16/2018 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 16, 2018 Category: Drugs & Pharmacology Source Type: news

Amgen Launches AMGEVITA ™ (Biosimilar Adalimumab) In Markets Across Europe
First Inflammation Biosimilar From Amgen's Portfolio to Launch in Europe THOUSAND OAKS, Calif., Oct. 15, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC). AMGEVITA is authorized for the treatment of inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidence of AS;...
Source: Amgen News Release - October 16, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

‘Patients Deserve to Know’: Trump Administration Wants Drug Commercials to Show Prices
TRENTON, N.J. — The federal government said Monday that it wants to force drugmakers to disclose prices for prescription medicines in their TV commercials. The drug industry’s main trade group said drug companies are only willing to disclose the prices on their websites, not in commercials, and they’ll start doing that next spring. Health and Human Services Secretary Alex Azar unveiled a proposal that would apply to all brand-name drugs covered by the Medicare and Medicaid programs, which is most medicines. “Patients deserve to know what a given drug could cost when they’re being told about th...
Source: TIME: Health - October 16, 2018 Category: Consumer Health News Authors: LINDA A. JOHNSON / AP Tags: Uncategorized Healthcare onetime Source Type: news

Rivals line up to take on world’s best-selling drug
As the European patent on AbbVie’s Humira expires, biosimilars are ready to target $20bn market (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 14, 2018 Category: Pharmaceuticals Source Type: news

Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
Sandoz, a Novartis division and the global leader in biosimilars, announced a global resolution of all intellectual property (IP) related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz® (adalimumab)[1] for reference medicine Humira®* (adalimumab). (Source: World Pharma News)
Source: World Pharma News - October 12, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Abbvie settles Humira patent disputes with Novartis unit
Abbvie Inc said on Thursday it settled all patent disputes with Novartis AG, granting it a non-exclusive license to manufacture and sell a copycat version of blockbuster drug, Humira. (Source: Reuters: Health)
Source: Reuters: Health - October 11, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

3 Evolutionary Scientists Win Nobel Chemistry Prize
(STOCKHOLM) — Three researchers who “harnessed the power of evolution” to produce enzymes and antibodies that have led to a new best-selling drug and biofuels won the Nobel Prize in chemistry on Wednesday. Frances Arnold of the California Institute of Technology was awarded half of the 9-million-kronor ($1.01 million) prize, while the other half will be shared by George Smith of the University of Missouri and Gregory Winter of the MRC molecular biology lab in Cambridge, England. The Royal Swedish Academy of Sciences, which chose the winners, said Arnold, 62, conducted the first directed evolution of enzym...
Source: TIME: Science - October 3, 2018 Category: Science Authors: JIM HEINTZ and DAVID KEYTON / AP Tags: Uncategorized nobel prize onetime Source Type: news

EU Approves Fifth Copy of AbbVie's $18 Bln Drug Humira EU Approves Fifth Copy of AbbVie's $18 Bln Drug Humira
Europe has approved a fifth copy of AbbVie ' s $18-billion-a-year biologic drug Humira (adalimumab) – the world ' s best-selling prescription medicine – ramping up competition among makers of less-expensive biotech drugs.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 21, 2018 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news

Mylan to launch Humira biosim in Europe
Mylan and Fujifilm Kyowa Kirin Biologics announced that the European Commission has granted marketing authorization for Hulio, a biosimilar to AbbVie ' s Humira. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - September 21, 2018 Category: Pharmaceuticals Source Type: news

California Sues Drug Maker AbbVie for Allegedly Paying Doctors to Prescribe Humira
A lawsuit filed Tuesday in California claims that pharmaceutical company AbbVie used cash, gifts, and services to induce doctors to overprescribe the widely used drug Humira, ignoring the medicine ' s potentially lethal side effects. Speaking in a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 20, 2018 Category: General Medicine Source Type: news

EU approves fifth biosimilar for blockbuster Humira drug
Mylan (NSDQ:MYL) and Fujifilm Kyowa Kirin Biologics said today that the European Commission gave the companies marketing authorization for Hulio, a biosimilar to AbbVie‘s (NYSE:ABBV) billion-dollar Humira product. Mylan said it plans to launch Hulio across particular markets in Europe on or after Oct. 16. The drug is the fifth product authorized by the EC as a biosimilar for AbbVie’s Humira. There is no biosimilar for Humira in the U.S. Get the full story at our sister site, Drug Delivery Business News. The post EU approves fifth biosimilar for blockbuster Humira drug appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 20, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Pharmaceuticals Regulatory/Compliance Wall Street Beat AbbVie fujifilm Mylan Source Type: news

Morning Break:'Cool' E-Cig Warnings; Humira Kickback Suit; Kidney Stones as Art?
(MedPage Today) -- Health news and commentary from around the Web gathered by the MedPage Today staff (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 20, 2018 Category: American Health Source Type: news

EU approves fifth copy of AbbVie's $18 billion drug Humira
Europe has approved a fifth copy of AbbVie's $18-billion-a-year biologic drug Humira – the world's best-selling prescription medicine – ramping up competition among makers of less-expensive biotech drugs. (Source: Reuters: Health)
Source: Reuters: Health - September 20, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Mylan, Fujifilm win EU okay for copy of AbbVie's Humira
Mylan and Fujifilm Kyowa Kirin Biologics said on Thursday they had won European approval to market a cheaper copy of AbbVie's $18-billion-a-year biologic drug Humira, the world's best-selling prescription medicine. (Source: Reuters: Health)
Source: Reuters: Health - September 20, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Health Highlights: Sept. 20, 2018
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: California Sues Drug Maker AbbVie for Allegedly Paying Doctors to Prescribe Humira A lawsuit filed Tuesday in California claims that... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 20, 2018 Category: General Medicine Source Type: news